ARRY Shines A BEACON, So Long To JUNO And BIVV, Exciting Time Ahead For GEMP

Array BioPharma Inc. gained 18.42% to close Monday's trading at $15.56. The Company's phase III trial evaluating the triplet combination of Encorafenib, Binimetinib, and Cetuximab, in patients with BRAF-mutant metastatic colorectal cancer, dubbed BEACON, has demonstrated an 8 month median progression-free survival. The enrollment in the randomized portion of the trial is ongoing.

from RTT - Biotech http://ift.tt/2rw9TMY
via IFTTT